Abstract
Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the worlds poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third of the world population is infected, though asymptomatically, with latent TB and is at risk of developing active TB disease during their lifetime. The current TB epidemic is fuelled by co-infection with HIV, the rise of multidrug-resistant strains, and the ability of the bacterium to become dormant in the lungs and to be reactivated in immunocompromised people. Despite medical advances over the last decades, including the genomic and proteomic revolution, TB still is a highly neglected disease. However, the search for new TB drugs is gaining momentum. Several efforts are underway to develop new drugs, within the academia, the pharmaceutical industry and as public private partnerships. This review will provide a chemical, biological and pharmacological overview of the six drug candidates currently in clinical development. Moxifloxacin (fluoroquinolone), TMC207 (diarylquinoline), PA-824 and OPC-67683 (nitroimidazoles), LL3858 (pyrrole) and SQ109 (ethambutol analogue) will be presented.
Keywords: Infectious disease, Mycobacterium tuberculosis, Moxifloxacin, TMC207, PA824, OPC67683, LL3858, SQ109
Current Bioactive Compounds
Title: New Anti-Tuberculosis Drugs in Clinical Development: An Overview
Volume: 5 Issue: 2
Author(s): Jerome Guillemont, Frederic Lieby-Muller, Nacer Lounis, Wendy Balemans, Anil Koul and Koen Andries
Affiliation:
Keywords: Infectious disease, Mycobacterium tuberculosis, Moxifloxacin, TMC207, PA824, OPC67683, LL3858, SQ109
Abstract: Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the worlds poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third of the world population is infected, though asymptomatically, with latent TB and is at risk of developing active TB disease during their lifetime. The current TB epidemic is fuelled by co-infection with HIV, the rise of multidrug-resistant strains, and the ability of the bacterium to become dormant in the lungs and to be reactivated in immunocompromised people. Despite medical advances over the last decades, including the genomic and proteomic revolution, TB still is a highly neglected disease. However, the search for new TB drugs is gaining momentum. Several efforts are underway to develop new drugs, within the academia, the pharmaceutical industry and as public private partnerships. This review will provide a chemical, biological and pharmacological overview of the six drug candidates currently in clinical development. Moxifloxacin (fluoroquinolone), TMC207 (diarylquinoline), PA-824 and OPC-67683 (nitroimidazoles), LL3858 (pyrrole) and SQ109 (ethambutol analogue) will be presented.
Export Options
About this article
Cite this article as:
Guillemont Jerome, Lieby-Muller Frederic, Lounis Nacer, Balemans Wendy, Koul Anil and Andries Koen, New Anti-Tuberculosis Drugs in Clinical Development: An Overview, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788451975
DOI https://dx.doi.org/10.2174/157340709788451975 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Non-Invasive Biomarkers of Lung Inflammation in Smoking Subjects
Current Medicinal Chemistry Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Natural and Acquired Macrolide Resistance in Mycobacteria
Current Drug Targets - Infectious Disorders Biological Properties of Yeast-based Mannoprotein for Prospective Biomedical Applications
Combinatorial Chemistry & High Throughput Screening Pre-Exposure Prophylaxis - One More Tool for HIV Prevention
Current HIV Research Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry The Overlapping Syndromes of the Pick Complex
Current Alzheimer Research Preface [Hot Topic: Antimycobacterial Drugs: Current Status and Future Prospects (Executive Editor: Haruaki Tomioka)]
Current Pharmaceutical Design Reverse Pharmacognosy: Another Way to Harness the Generosity of Nature
Current Pharmaceutical Design Heterocyclic N-oxides - A Promising Class of Agents against Tuberculosis, Malaria and Neglected Tropical Diseases
Current Pharmaceutical Design Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies Is There a Role for Antioxidants in the Prevention of Infection-Associated Carcinogenesis and in the Treatment of Infection-Driven Tumors?
Current Topics in Medicinal Chemistry Strategically Placed Trifluoromethyl Substituent in the Realm of Antitubercular Drug Design
Current Drug Therapy Adverse Effects and Drug Interactions of Biologic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Trace and Minor Element Concentrations in Aqueous Extract of the Herbal Medicinal Plants Tamarindus indica and Hibiscus sabdiffora
Current Nutrition & Food Science Identifying the Structural Features of Diphenyl Ether Analogues for InhA Inhibition: A 2D and 3D QSAR Based Study
Letters in Drug Design & Discovery Phylogenetic and Functional Classification of ATP-Binding Cassette (ABC) Systems
Current Protein & Peptide Science Synthesis, Characterization, Biological Activity and Voltammetric Behavior and Determination of Cefaclor Metal Complexes
Current Analytical Chemistry